Clinical Trial

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-31.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-06
Trial Details
NCT Number NCT07108699
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 180 participants
Start Date 2025-08-13
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08